The cancer drugs fund in practice and under the new framework

PharmacoEconomics. 2019:1-10.


Sabry-Grant C, Malottki K, Diamantopoulos A


This is the first study investigating the Cancer Drugs Fund under the new framework. We developed a method to systematically identify documents and collect information regarding the drugs included in the Fund.



Designed a protocol to identify, collect and synthesise data on the drugs included in the Cancer Drugs Fund under the new framework


NICE and SMC documents were reviewed to capture information pertaining to drugs involved in a managed access agreement on the Cancer Drugs Fund


Information was collected and synthesised on clinical and economic aspects of the treatments included in the Cancer drugs Fund


Considered recent criticism of the CDF and how the new framework in practice may address or confirm those limitations

Publications in other disease areas

Atrial fibrillation

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke


Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom

Idiopathic pulmonary fibrosis

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review


The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis

Rheumatoid arthritis

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK


Venous thromboembolism

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective